Emdogain Implementation With Transcrestal Sinus Lifting and Dental Implant Placement (NCT05507047) | Clinical Trial Compass
CompletedPhase 4
Emdogain Implementation With Transcrestal Sinus Lifting and Dental Implant Placement
Turkey (Türkiye)24 participantsStarted 2017-01
Plain-language summary
The aim of this study is to evaluate the clinical and radiographic results of implants placed using osteotome sinus floor elevation (OSFE) with and without simultaneous enamel matrix derivative (EMD) application.
Who can participate
Age range18 Years – 99 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* partial edentulism in the maxillary posterior region for at least 4 months from tooth loss and require implant treatment
* adequate bone thickness for primary stabilization
* residual bone height ranged from 4 mm to 6 mm
* systemic and local conditions compatible with implant placement and sinus floor elevation
* antagonist teeth
Exclusion Criteria:
* uncontrolled diabetes mellitus or other systemic disorders (such as; hepatitis, tuberculosis, AIDS)
* pregnancy
* untreated periodontal disease
* endodontic lesions or other oral disorders
* heavy smokers (≥10 cigarettes per day)
* acute or chronic rhinitis
* sinusitis or pathology in sinus
* inadequate residual bone height and quality to achieve implant stability
* previous implant treatment/failure or bone augmentation in the implant site
* sinus perforation as confirmed via Valsalva maneuver
* insufficient primary implant stability measured by RFA
What they're measuring
1
endo-sinus bone gain
Timeframe: CBCT will be evaluated at initiation of study (T0), at 3th month (T1) and 12th month (T2)